文献速递肝病

氟喹诺酮类药物诱导肝损伤的临床特征与HLA关联:药物性肝损伤网络研究结果

Clinical and HLA Associations of Fluoroquinolone-Induced Liver Injury: Results From the Drug-Induced Liver Injury Network.
PubMed 文献 · Am J Gastroenterol · 2025-04-10

该研究分析了2004至2022年药物性肝损伤网络登记的61例氟喹诺酮类相关肝损伤病例,发现该损伤潜伏期短、肝损伤模式多样,且与HLA-DQA1*03:01和HLA B*57:01等位基因携带频率升高相关,同时存在慢性化和死亡风险。

要点

  • 氟喹诺酮类肝损伤中位潜伏期12天,44%为肝细胞型、30%混合型、26%胆汁淤积型。
  • HLA-DQA1*03:01携带频率病例组38% vs 对照组19%,HLA B*57:01为15% vs 6%。
  • 两等位基因合并携带频率病例组48% vs 对照组24%(P=0.0001)。

核心结论

  • 氟喹诺酮类肝损伤为类效应,潜伏期短、肝损伤模式多样,并具有显著的慢性化和死亡风险。
  • 该损伤与HLA-DQA1*03:01和HLA B*57:01存在显著关联。

研究设计与样本

  • 研究分析了2004年至2022年间纳入药物性肝损伤网络的氟喹诺酮类相关肝损伤病例。
  • HLA I类和II类等位基因通过Illumina MiSeq平台测序。

主要发现

  • 共纳入61例病例,其中环丙沙星32例、左氧氟沙星22例、莫西沙星7例。
  • 治疗中位持续时间7天(范围2-54天),中位年龄53岁(范围22-80岁),女性占67%。
  • 中位起病潜伏期12天(范围2-1,370天),肝损伤模式为肝细胞型44%、混合型30%、胆汁淤积型26%。
  • 中位恢复时间65天,但13%在6个月时仍有持续损伤,15%死亡(其中11%死于肝衰竭)。
  • HLA-DQA1*03:01携带频率病例组38% vs 对照组19%,HLA B*57:01为15% vs 6%,两等位基因合并携带频率病例组48% vs 对照组24%(P=0.0001)。

关键数值与推荐

  • HLA-DQA1*03:01携带频率病例组38% vs 对照组19%。
  • HLA B*57:01携带频率病例组15% vs 对照组6%。
  • 两等位基因合并携带频率病例组48% vs 对照组24%(P=0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Fluoroquinolones (FQ) have a favorable safety profile, but the risk of drug-induced liver injury (DILI) is well described. The aim of this study was to identify clinical features and HLA genetic variants associated with FQ-DILI in a large national registry. METHODS: Analysis of FQ-DILI cases enrolled in DILI Network between 2004 and 2022. HLA class I and II alleles were sequenced by the Illumina MiSeq platform. RESULTS: Sixty-one cases (32 ciprofloxacin, 22 levofloxacin, 7 moxifloxacin) were included. Clinical features between the 3 drugs were similar. The median duration of therapy was 7 (range 2-54) days, median age 53 (range 22-80) years, and 67% were female. Median latency to onset was 12 (range 2-1,370) days with 44% hepatocellular, 30% mixed, and 26% cholestatic pattern of liver injury. Median time to recovery was 65 days, but 13% had persistent injury at 6 months, 15% died (11% because of liver failure). Two HLA alleles were associated with an increased risk of liver injury: HLA-DQA1*03:01 (carriage frequency 38% in cases vs 19% in controls) and HLA B*57:01 (15% vs 6%). There was a significant difference between the combined carriage frequency of the 2 alleles of 48% in cases vs 24% controls ( P = 0.0001). No clinical characteristics or outcomes were associated with carriers compared with noncarriers. DISCUSSION: FQ DILI is a class effect that presents with a short latency, variable pattern of liver injury, and carries a significant risk of chronicity and mortality. There is a significant association with HLA-DQA1*03:01 and HLA B*57:01 .

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Ahmad J, Dellinger A, Nicoletti P, et al. Clinical and HLA Associations of Fluoroquinolone-Induced Liver Injury: Results From the Drug-Induced Liver Injury Network. Am J Gastroenterol. 2025. PMID: 40207808. doi:10.14309/ajg.0000000000003457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。